ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
1/1
0/0

A Caged E3 Ligase Ligand for PROTAC-Mediated Protein Degradation with Light

preprint
revised on 19.12.2019 and posted on 23.12.2019 by Cyrille Kounde, Maria M. Shchepinova, Edward Tate
A caging group has been appended to a widely used Von Hippel Lindau (VHL) E3 ligase ligand for targeted protein degradation with PROTACs. Proteolysis is triggered only after a short irradiation time allowing spatiotemporal control of the protein’s fate.

Funding

EP/R512540/1

History

Email Address of Submitting Author

e.tate@imperial.ac.uk

Institution

Imperial College London

Country

United Kingdom

ORCID For Submitting Author

0000-0003-2213-5814

Declaration of Conflict of Interest

M.M. and J.D.H are employees and shareholders of GlaxoSmithKline (GSK). E.W.T. is a Director and shareholder of Myricx Pharma Ltd. M.D.R is an employee of Merck Sharp & Dohme.

Licence

Exports

Read the published paper

in Chemical Communications

Logo branding

Licence

Exports